NCT02452034View on ClinicalTrials.gov

Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)

PHASE1CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

September 7, 2015

Primary Completion Date

June 26, 2018

Study Completion Date

September 3, 2018

Conditions
Neutropenia
Interventions
DRUG

Posaconazole IV solution

Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.

DRUG

Posaconazole powder for oral suspension

Posaconazole once daily by PFS for a minimum of 10 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02452034 - Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097) | Biotech Hunter | Biotech Hunter